3-(2-amino-6-quinazolinyl)-4 methyl-N-(3-(trifluoromethyl)phenyl)benzamide | 882664-95-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-amino-6-quinazolinyl)-4 methyl-N-(3-(trifluoromethyl)phenyl)benzamide
• 英文别名: 3-(2-Aminoquinazolin-6-Yl)-4-Methyl-N-[3-(Trifluoromethyl)phenyl]benzamide
• CAS: 882664-95-1
• 化学式: C₂₃H₁₇F₃N₄O
• 分子量: 422.409
• InChiKey: YEIASMOUYNOXGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  80.9
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-(2-amino-6-quinazolinyl)-4 methyl-N-(3-(trifluoromethyl)phenyl)benzamide 、 异氰酸乙酯 在 二氯甲烷,丙烷-2-酮 、 甲醇 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以to yield 3-(2-(((ethylamino)carbonyl)amino)-6-quinazolinyl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide as a white solid的产率得到3-(2-(((ethylamino)carbonyl)amino)-6-quinazolinyl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide
  参考文献：
  名称：

  Aryl nitrogen-containing bicyclic compounds and methods of use

  摘要：

  本发明涉及一种新的化合物类别，对蛋白激酶介导的疾病，包括炎症、癌症和相关疾病的预防和治疗有用。该化合物具有一般的式子I，其中A1、A2、A3、B、R1、R2、R3和R4在此定义。因此，本发明还涉及包含本发明化合物的制药组合物，使用本发明化合物和组合物预防和治疗激酶介导的疾病的方法，以及用于制备本发明化合物的中间体和过程。

  公开号：

  US20070054916A1
• 作为产物：
  描述：

  3-(2-amino-6-quinazolinyl)-4-methylbenzoic acid 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 3-(2-amino-6-quinazolinyl)-4 methyl-N-(3-(trifluoromethyl)phenyl)benzamide
  参考文献：
  名称：

  Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck:  Synthesis, SAR, and in Vivo Anti-Inflammatory Activity

  摘要：

  The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer (NK) cells. Genetic evidence in both mice and humans demonstrates that Lck kinase activity is critical for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation. Selective inhibition of Lck is expected to offer a new therapy for the treatment of T-cell-mediated autoimmune and inflammatory disease. Screening of our kinase-preferred collection identified aminoquinazoline 1 as a potent, nonselective inhibitor of Lck and T cell proliferation. In this report, we describe the synthesis and structure-activity relationships of a series of novel aminoquinazolines possessing in vitro mechanism-based potency. Optimized, orally bioavailable compounds 32 and 47 exhibit anti-inflammatory activity (ED50 of 22 and 11 mg/kg, respectively) in the anti-CD3-induced production of interleukin-2 (IL-2) in mice.

  DOI：

  10.1021/jm0605482

文献信息

• ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：AMGEN INC.

  公开号：EP1836174A2

  公开（公告）日：2007-09-26
• IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS
  申请人：CAMP4 THERAPEUTICS CORPORATION

  公开号：US20210254056A1

  公开（公告）日：2021-08-19

  The present invention provides methods and compositions for the evaluation, alteration and/or optimization of gene signaling. Methods and systems are also provided which exploit the information generated in the identification of new targets and non-canonical signaling pathways.
• [EN] ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSES BICYCLIQUES AZOTES D'ARYLE ET LEURS PROCEDES D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2006039718A2

  公开（公告）日：2006-04-13

  The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I, wherein A1, A2, A3, B, R1, R2, R3 and R4 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.